Background/Aims: Choriocarcinoma (CC) is a highly aggressive gestational trophoblastic neoplasia; however, the underlying molecular mechanisms of its invasiveness and metastasis remain poorly understood. Human secreted frizzled-related protein 2 (SFRP2) could function as a tumor promoter or suppressor in different tumors, yet the role it plays in CC's invasion and metastasis is thoroughly unclear. The current study was aimed to explore the function and underlying mechanism of SFRP2 in CC. Methods: The expression of SFRP2 in CC tissues was examined via immunohistochemistry. The methylation level and expression of SFRP2 in CC cell lines, JEG-3 and JAR were examined via bisulfite sequencing PCR (BSP), western blotting and quantitative RT-PCR. The biological role of increasing expressed SFRP2 through its promoter demethylation with 5-Aza-2'-deoxycytidine (5-Aza) was examined by a series of in vitro functional studies. Furthermore, lentivirus transfection technology was adopted to investigate the biological roles of SFRP2 knockdown in JEG-3 and JAR cells in vitro and in vivo. Moreover, its downstream signaling pathway was investigated. Results: SFRP2 was downregulated in CC tissues, and its expression was inversely related to its promoter hypermethylation frequency in JEG-3 and JAR cells. Increased SFRP2 through its promoter demethylation inhibited cell migration, invasion and colony formation in JEG-3 and JAR cells, whereas decreased SFRP2 reversed the epithelial-mesenchymal transition (EMT) process and stemness in JEG-3 and JAR cells both in vitro and vivo. Mechanistically, SFRP2 regulated the EMT and stemness of CC cell lines via canonical Wnt/β-catenin signaling, validated by the usage of a Wnt activator
Therefore, in this study, we will investigate the expression level of SFRP2 in CC specimens and CC cell lines, JEG-3 and JAR. Furthermore, we will determine the function of SFRP2 in CC and explore its role in EMT phenotypes and the stemness of CC.
Materials and Methods

Cell culture and reagents
The human first trimester extravillous trophoblast cell line (HTR-8) cultured in RPMI-1640 medium and human embryonic kidney 293T cells, as well as two human CC cell lines (JAR and JEG-3) cultured in DMEM medium supplemented with 10% fetal bovine serum and incubated in a 37˚C humidified incubator that contained 5% CO2, were obtained from the American Type Culture Collection (Manassas, VA, USA). 5-Aza-2'-deoxycytidine (5-Aza; ab120842, Abcam, Cambridge, UK) was added to the culture medium to induce demethylation in JAR and JEG-3 cells; XAV 939 (S1180, Selleckchem, Houston, TX) was added to the culture medium as a Wnt/β-catenin pathway inhibitor at a final concentration of 2 μM. BML-284 (sc-222416, Santa Cru, USA) was added to the culture medium as a Wnt/β-catenin pathway activator at a final concentration of 5 μM. For the control cells, an equal dose of dimethylsulfoxide (DMSO) was added to the medium.
Real-time reverse transcription polymerase chain reaction (qRT-PCR)
Total cellular RNA was extracted using RNAfast 200 reagents (Fastagen Biotechnology, Shanghai, China) and was quantified by absorbance at 260 nm. The RNA (2 μg) sample was reversely transcribed with PrimeScript RT Master Mix, and quantitative PCR was performed with SYBR-Green PCR Master Mix (Takara Bio, Dalian, China). The gene-specific primer sequences are shown in Table 1 . GAPDH was used as the internal control. The threshold cycle (Ct) value for triplicate reactions was averaged. The melting curve for the primers was analyzed to confirm the specificity of the PCR products. The relative expression of mRNA for each target gene was calculated as follows: ∆Ct = Ct (target) -Ct (GAPDH), ∆∆Ct = ∆Ct -∆Ct (calibrator), and the fold changes in mRNAs were calculated through relative quantification (2 -∆∆Ct ).
Western blotting
Cells were washed three times with cold PBS and lysated in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, and 0.5% sodium deoxycholate) protease inhibitors (1% inhibitor cocktail and 1 mM PMSF) (Sigma) on ice. Approximately 20 µg of protein were separated with 10-12% SDS-PAGE gel, transferred onto nitrocellulose membranes, and blocked with 5% non-fat dry milk in TBST at room temperature for 1 h. The membrane was subsequently incubated with primary antibody with different dilutions by 5% BSA at 4 °C overnight, followed by a TBST wash and 1-h incubation with HRPconjugated secondary antibodies (Licor, Rockford, IL, USA) at room temperature.
The membranes were scanned using a Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, Hercules, CA, USA). The antibodies used are shown in Table 2 . Loading differences were normalized using β-actin.
Table 1. Primers used for qRT-PCR
Gene
Primers (sense/antisense 5'-3') Product length (bp) Tm (°C)  SFRP1  TCCCTGTGACAACGAG  207  60  GTCCTTCTTCTTGATGGGC  SFRP2  GGAGACCAAGAGCAAGACCAT  228  60  GCACTGCAAGCTGTCTTTGA  SFRP3  TCGAGCAGTTCGAAGGTCTG  184  60  CACGAGTGGCGGTACTTGAT  SFRP4  CACATCCTGCCCCATCAAGA  161  59  TCCTGAACTGTTCTCCGCTG  SFRP5  CAGATGTGCTCCAGTGACTTTG  184  60  AGAAGAAAGGGTAGTAGAGGGAG  β-catenin  TTCGCCTTCACTATGGACTACC  175  59  GCACGAACAAGCAACTGAACTA  Dvl3  TGGACGACGATTTCGGAGTG  139  60  TTATCAGCACAGAAGGGGGC  Twist  CGCCCCATGATATGGGTAGC  174  60  CCATGACTCGCTGGTTCTGA  E-cadherin  GGGCTCAAGTGACTCGTAACGA  202  59.9  CAGCCGCTTTCAGATTTTCATC  N-cadherin  ACTTGCCAGAAAACTCCAGGG  209  60  CCCTAAATGAAACCGGGCATT  Vimentin  AGCTCTGCGTGAAGTTCGAT  175  59  TGCCTGGACTTGTCTACGTG  MMP2  CACATCTGGGCAGTTGCTAA  144  59  TCTGGGGCAGTCCAAAGAAC  MMP9  TTCCAAACCTTTGAGGGCGA  164  60  CTGTACACGCGAGTGAAGGT  GAPDH  AAATCAAGTGGGGCGATGCT  186 
MTT assay
The tumor cell viability in the presence of increasing 5-Aza concentrations in two CC cell lines was measured by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) assay. The absorbance was measured at 490 nm using a universal microplate reader (Model ELx800; BioTek Instruments, Inc., Winooski, VT, USA). The 5-Aza concentrations ranged from 0 µM in the DMSO control to 20 µM, whereas the incubation period was 24 h, 48 h and 72 h. The viability of the treated cells was reported relative to the DMSO control.
Bisulfite sequencing PCR (BSP)
Genomic DNA samples were obtained from HTR-8, and JEG-3 and JAR were purified using DNAzol (Invitrogen). Bisulfite treatment of 2.0 μg genomic DNA of placental tissues and trophoblast-like cell lines was performed using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The base SFRP2 sequence was as follows:
The primers for bisulfite-converted DNA were SFRP2-F: 5'-GGTAATTTAGTAGAAATTTCGG-3' and MEST-R: 5'-TACGTTAAAAATACCCCTCAC-3'. Amplified bisulfate PCR products were subcloned into the TA vector system (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions. Five clones were randomly selected for specific regions of the gene and were sent to Sangon Biotech (Shanghai, China) for sequencing.
Enzyme-linked immunosorbent assay
To measure the SFRP2 concentration in cultural supernatants, a sandwich enzyme-linked immunosorbent assay (ELISA) was performed using an SFRP2 ELISA kit (F00857, Xitang biotechnology, Shanghai, China) according to its protocol.
Plasmid construction and lentiviral infection
The plasmids were constructed according to standard methods. All structures were verified by appropriate restriction digestion and/or sequencing. The sequences of SFRP2 short hairpin RNAs (shRNAs) were as follows: shSFRP2-1: 5ʹ-GATCCGCCACCCGAATCTTGTAGAAATTCAAGAGATTTCTACAAGATTCGGGT GGTTTTTTGG-3ʹ, shSFRP2-2: 5ʹ-GATCCGGAAGCTCCAAAGGTATGTGAATCAAGAGTTCACATACCTTTGGAG CTTCTTTTTTGG-3ʹ. The shRNAs were subsequently transfected with X-tremeGENE HP DNA transfection reagents (Roche Diagnostics, Indianapolis, IN, USA) into the pLKO.1 lentiviral vector (Addgene) following the manufacturer's instructions. For lentiviral infection, JEG-3 and JAR cells were plated overnight and subsequently infected with lentivirus in the presence of polybrene (8 μg/ml, Sigma-Aldrich). Lentivirus 
Transwell assay
Cell migration and invasion were performed via a Boyden chamber assay (Millipore, Chaffhausen, Switzerland). For invasion, the upper chamber of an 8-mm pore size coated with 60 µl Matrigel (Sigma, St. Louis, MO, USA) was incubated in 37 °C with 5% CO2 for 4 h. Then, 8×10
4 cells were seeded in the upper chamber in 200 µl serum-free DMEM medium, and 800 µl DMEM medium with 20% serum were added in the lower chamber of a 24-well plate. After 24 h, the chambers were washed with PBS (pH 7.4) three times, fixed with 4% formalin for 10 min, and stained with crystal violet (0.01% in ethanol, Sigma) for 20 min. Five random fields were assessed under the inverted microscope at × 20 magnification, and the cell number was counted. For the migration assay, 4×10
4 cells were directly seeded in the upper chamber without Matrigel, and the rest of the protocol was conducted in the same manner as the invision assay. The relative invasion or migration ability was expressed as a ratio of the control cells.
Scratch wound assay JEG-3 and JAR cells after lentiviral transfection (shSFRP2 and vector) were scratched in 6-well plates with a pipette tip when the cells were at 80% confluence. Serum-free medium was subsequently added to the plates, and the width of the scratches was measured at 0 h, 24 h, and 48 h after scratching.
Immunofluorescence microscopy For immunofluorescence (IF) staining, approximately 8×10
3 cells were spotted on poly-D-lysinecoated slides (Thermo Fisher), fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 for 15 min and blocked in 5% BSA for 30 min. The cells were subsequently incubated with primary antibody (β-catenin, 1:100 in 5% BSA) at 4˚C overnight, followed by Alexa fluor 488 second antibody (1:150 in 5% BSA) for 1 h and DAPI for 5 min. Slides were scanned and photographed using an Olympus BX51 Microscope (Olympus, Tokyo, Japan).
Colony formation assay
Cells were seeded in a six-well plate at a density of 1000 cells/well and were grown for 2 weeks. The cell colonies that emerged were washed with phosphate-buffered saline, fixed with 4% formalin for 10 min, and stained with crystal violet (0.01% in ethanol, Sigma) for 20 min. The number of colonies from each well was counted under an inverted microscope.
Tumor xenograft model
Female athymic nude mice at the age of 4-5 weeks were used according to the protocol, which was in accordance with the guidelines of the Institutional Animal Care and Use Committee of Xi'an Jiaotong University. In all, 200 μl serum-free DMEM medium that contained Matrigel (2:1, v/v) with 5 × 10 6 JEG-3 sublines (vector or shSFRP2-1 and SFRP2-2) were subcutaneously injected into both flanks. The mice were sacrificed, xenografts were harvested at day 14, and tumors were weighed and measured. A small part of the individual xenograft was fixed with 4% paraformaldehyde, embedded in paraffin and subsequently stained by immunohistochemistry. The remaining xenografts were rapidly placed in liquid nitrogen and used for western blotting and qRT-PCR.
Clinical specimens and immunohistochemistry
Paraffin sections of the first trimester villus (FTV), HM, invasive mole (IM) and CC were obtained from the Department of pathology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
The specimens were histologically diagnosed at this hospital from 2013 to 2017. For the use of these clinical materials for research purposes, prior patient consents and approval from the Institutional Research Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University were obtained. The immunohistochemistry was performed using the EnVision™ system (Dako, Carpinteria, CA, USA). Tissue sections were de-paraffinized, rehydrated and subjected to 5-min pressure cooker antigen retrieval to the intensity of the staining (0, none; 1, weak; 2, intermediate; 3, strong) and the percentage of positive cells (0, 0-5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; 4, 76-100%). Thus, the former multiplied the latter to obtain the final result: negative (0 score), weak (1-4 score), moderate (5-8 score) and strong (9-12 score).
Statistical analysis
All experiments were repeated at least three times. All statistical analyses were performed using GraphPad Prism version 5.0 software (GraphPad Software, La Jolla, CA, USA). All data were presented as the mean ± S.E.M., and the differences were compared via the two-tailed Student's t-test between two groups or one-way ANOVA with a Bonferroni correction among several groups. *P<0.05, ** P<0.01, *** P<0.001.
Results
SFRP2 is downregulated in human CC tissues and CC cell lines
To investigate the expression pattern of SFRP2 in CC tissues, we performed immunohistochemical staining in 7 cases of CC, 9 cases of IM, 16 cases of HM and 16 cases of FTV. As shown in Fig. 1A , B and C, we determined that the expression of SFRP2 protein was lower in the CC and IM tissues than the HM tissues and FTV (P﹤0.001), whereas there was no difference between CC and IM or HM and FTV. Moreover, we analyzed the expression of . Consistently, the result showed that SFRP2 was decreased in the JEG-3 and JAR cells compared to HTR-8 at both the mRNA and protein levels (Fig. 1D ). Many studies regarding other cancers have reported that SFRP2 was downregulated through CpG hypermethylation of the gene promoter. Thus, we wondered whether the low expression of SFRP2 in CC was related to hypermethylation. To clarify this issue, we assessed the methylation level of the SFRP2 gene promoter. We only conducted BSP in HTR-8, JEG-3 and JAR cells because it was extremely difficult to obtain fresh CC tissues; we showed that the SFRP2 promoter methylation frequency was significantly increased in the JEG-3 and JAR cells compared to the HTR-8 cells (Fig. 2E, F and J) . Overall, the data suggested that there was a correlation between SFRP2 promoter methylation and decreased SFRP2 expression in both JEG-3 and JAR cells, thus implying that decreased SFRP2 may be associated with the tumorigenesis and progression of CC. 
Restoration of SFRP2 expression is induced by 5-Aza in CC cell lines
First, the BSP test showed that the methylation level was higher in the JEG-3 and JAR cells than the HTR-8 cells, which implies that there was a potential relationship between the decreased expression and high methylation frequency of SFRP2 in CC. To ascertain this association, we utilized 5-Aza, a methyltransferase inhibitor, to validate the expression profile of SFRP2. An MTT assay was employed to determine the optimal concentration of 5-Aza used to induce demethylation in JEG-3 and JAR cells (Fig. 2A) ; the results indicated that 5-Aza had a concentration-dependent and time-dependent effect on cell viability in both JEG-3 and JAR cells. With the increasing concentration of treatment with 5-Aza, the protein and mRNA levels of SFRP2 significantly increased as shown in Fig. 2B and Fig. 2C , respectively. The ELISA test simultaneously showed a dose effect of 5-Aza on SFRP2 expression at the concentrations of 0, 1.25, 2.5, and 5.0 µM after 48 h treatment in JEG-3 and JAR cells (Fig.  2D) . Furthermore, the BSP test showed that demethylation of the SFRP2 gene was efficiently induced by 5-Aza at the concentrations of 0, 1.25, 2. 
Demethylated SFRP2 promoter cripples migratory and invasive abilities in CC cells
We initially investigated the change of the EMT phenotype in JEG-3 and JAR cells. Western blotting assay showed that the epithelial marker (i.e., E-cadherin) increased, whereas the mesenchymal markers (i.e., N-cadherin, Vimentin, and Twist), MMP2, and MMP9 decreased at the protein level in JEG-3 and JAR cells treated with 5-Aza compared with the DMSO control (Fig. 3A) . The Transwell assay subsequently indicated that in contrast to the DMSO control, the migratory and invasive abilities were strikingly inhibited in JEG-3 and JAR cells when treated with 5-Aza at the concentration of 5 µM for 48 h (Fig. 3B) . The scratch wound assay simultaneously indicated that the CC cell lines JEG-3 and JAR treated with 5-Aza showed a weaken ability to migrate compared with the untreated cell lines, shown by quantification and representative images in Fig. 3C . Moreover, we explored the stemness transformation in CC cells lines. The expression of Oct4 and Nanog was decreased in JEG-3 and JAR cells after incubation with 5-Aza (Fig. 3D) . Moreover, the clone formation number in the JEG-3 and JAR cells treated with 5-Aza was substantially decreased compared with the untreated cells (Fig.  3E) . Overall, increased SFRP2 through demethylation by 5-Aza increased the expression of SFRP2 and subsequently crippled the EMT phenotype and stemness, as well as significantly prohibited cell migration and invasion in JEG-3 and JAR cells.
SFRP2 knockdown promotes EMT phenotype and stemness in CC cells
The efficiency of the SFRP2 knockdown was confirmed by western blotting assay and qRT-PCR (Fig. 4A) . First and foremost, the western blotting results indicated that the epithelial marker (i.e., E-cadherin) was decreased, whereas the mesenchymal markers (i.e., N-cadherin and Twist), MMP2, and MMP9 were increased in the SFRP2 knockdown JEG-3 and JAR cells compared with the empty vector control (Fig. 4B) . Furthermore, the number of migratory and invasive cells substantially increased in the SFRP2-deficient JEG-3 and JAR cells in contrast to the empty vector control (Fig. 4C) . Moreover, the migratory distance was augmented when SFRP2 was knocked down (Fig. 4D) . Together, the data implied that SFRP2 knockdown could promote the EMT phenomenon in JEG-3 and JAR cells. Furthermore, we examined the stemness in SFRP2-deficient JEG-3 and JAR cells. The western blotting assay demonstrated that the expression of Oct4 and Nanog was increased (Fig. 5A) . Moreover, the number of clone formation was increased in the SFRP2-deficient JEG-3 and JAR cells (Fig. 5B) . Thus, these data suggested decreased SFRP2 promoted the migratory and invasive potential of JEG-3 and JAR cells. 
SFRP2 regulates EMT phenotype and stemness via Wnt/β-catenin pathway in CC cells
To analyze the effect of the demethylation of the SFRP2 gene promoter on the activation of canonical Wnt signaling, we determined the key components, such as Dvl3, GSK-3β, p-GSK-3β (the inactivated form of GSK-3β) and β-catenin, at both the protein and mRNA levels ( Fig. 6A and Fig. 6B ). Western blotting assay determined that Dvl3, β-catenin and p-GSK-3β were downregulated in JEG-3 and JAR cells when treated with 5-Aza in contrast to the DMSO control, thus illustrating that 5-Aza could suppress canonical Wnt signaling. Moreover, IF showed that 5-Aza conspicuously inhibited nuclear retention of the dominated Wnt signaling factor, β-catenin, in JEG-3 and JAR cells, which further verifies the canonical Wnt signaling could be inhibited by 5-Aza (Fig. 6C) . Furthermore, we added a Wnt activator (BML-284) to JEG-3 and JAR cells treated with 5-Aza and showed that the activity of the Wnt pathway and EMT phenotype and stemness were regained at the protein level (Fig. 6D-F) . Taken together, the methylation-mediated loss of SFRP2 enhances CC cell migration and invasion via Wnt signaling. Thus, increased SFRP2 through its promoter demethylation with 5-Aza could increase SFRP2 expression, inhibit its nuclear retention and eventually lead to 
Transition and Stemness inactivation of the Wnt/β-catenin pathway, thus resulting in impaired abilities of migration and invasiveness in the CC cell lines JEG-3 and JAR.
We simultaneously determined that Dvl3, β-catenin and p-GSK-3β were elevated in SFRP2-deficient JEG-3 and JAR cells at both the protein and mRNA levels ( Fig. 7A and Fig.  7B ). To further elucidate the specific role of canonical Wnt signaling, we treated SFRP2-deficient JEG-3 and JAR cells with a specific inhibitor XAV 939 and determined that XAV 939 weakened the activity of Wnt/β-catenin signaling (Fig. 7C) . In addition, the cells treated with XAV 939 exhibited a decrease of the migratory and invasive capacity (Fig. 8A-B) and the reversal of the EMT phenotype and stemness markers (Fig. 7D and Fig. 8C ). SFRP2 knockdown promoted CC cell migration and invasion and stemness through activation of 
Transition and Stemness
the Wnt/β-catenin pathway. However, the stimulative effect could be partially blocked by the Wnt/β-catenin signaling inhibitor XAV 939. Thus, these data promoted us to propose that decreased SFRP2 expression may function as an invasive promoter via the reduced ability to antagonize canonical Wnt signaling in CC.
SFRP2 knockdown enhances tumor invasive potential in vivo
Therefore, to further confirm the connection between SFRP2 and CC invasion identified in vivo, we established the subcutaneous xenograft using JEG-3 expressing empty vector control non-targeting shRNA or SFRP2 shRNA. This study found that the expression of SFRP2 was low in CC tissues. To simulate the natural biological behavior in human body, we only examined the function of downregulated SFRP2 in vivo. We identified an increased tumor size and weight in the SFRP2 shRNA-transfected groups compared with the vector shRNAtransfected group (Fig. 9A) . Moreover, we examined the expression of SFRP2, β-catenin and MMP2 by IHC in the harvested xenografts; in line with the in vitro findings, JEG-3/shSFRP2 tumors exhibited lower SFRP2 expression with a strong β-catenin and MMP2 expression staining compared to the JEG-3/vector (Fig. 9B) . Furthermore, western blotting and qRT-PCR of the SFRP2, β-catenin, Dvl3 and EMT markers in xenograft tissues also showed the same changing trend identified in vivo (Fig. 9C-D) . These results indicated that SFRP2 knockdown promoted the invasiveness in CC in vivo. 
Discussion
Patients with metastatic CC typically require more courses of multi-agent chemotherapy and even potentially brain irradiation, thus posing substantial threats to women's reproductive ability and quality of life [22, 23] . Worse still, the final outcome remains unsatisfactory even when various treatment modalities are applied. Thus, it is extremely urgent to identify the molecular mechanisms implicated in CC invasion and metastasis and search for the therapeutic target for metastatic CC. We demonstrated that SFRP2 was decreased expressed in CC specimens and CC cell lines, and the low expressed SFRP2 could promote tumor invasion and metastasis in CC through the Wnt/β-catenin pathway both in vivo and in vitro.
Previous studies have supported SFRPs as tumor suppressors because their expression is often silenced in cancers by promoter hypermethylation. In recent years, numerous reports have reported SFRP2, a Wnt inhibitor, was downregulated through CpG island methylation at its gene promoter in various human cancers, including gastric carcinoma [24] , hepatocellular carcinoma [25, 26] , melanoma [27] and colorectal cancers [28] . However, whether the methylation of SFRP2, a member of SFRPs, may be involved in the pathogenesis of CC has not been well elucidated. In the present study, we showed that SFRP2 expression was decreased, whereas the methylation status was increased in CC cell lines and 5-Aza could restore the expression of SFRP2 through demethylation in JEG-3 and JAR cells. Thus, we hypothesized that SFRP2 may act as a tumor suppressor in the invasiveness and metastasis of CC. Next, to validate the role played by SFRP2 in CC, we examined the EMT phenotype and stemness, which were critical for the invasiveness and metastasis, in JEG-3 and JAR cells; the results indicated that increased SFRP2 through promoter demethylation by 5-Aza could restrain the migration and invasion ability, whereas SFRP2 knockdown could promote the migratory and invasive potential of JEG-3 and JAR cells. In addition, the effect of SFRP2 in stemness showed an identical trend. Most importantly, these phenomena were confirmed by similar results in vitro. Thus, it is conceivable that SFRP2 gene silencing through promoter hypermethylation contributes to the high potential of invasiveness and metastasis.
Moreover, studies have suggested that SFRP2 could inhibit the Wnt/β-catenin pathway, thus acting as a tumor suppressor [29, 30] . In contrast, several reports have claimed that SFRP2 induced tumor growth in certain malignancies, including glioma and renal cancer, by activating canonical Wnt signaling or stimulating angiogenesis via a calcineurin/NFAT as non-canonical Wnt transduction in breast cancer [31] . However, whether SFRP2 would function through the Wnt/β-catenin pathway in CC was ill-defined, and the previous findings prompted us to speculate the role of the Wnt/β-catenin pathway during this biological behavior. In the absence of Wnt signaling, GSK-3β phosphorylates cytoplasmic β-catenin, which makes it a target for degradation by the proteasome. However, during aberrant Wnt pathway signaling activation, GSK-3β is inactivated, which results in increased levels of unphosphorylated cytoplasmic β-catenin. This accumulation of cytoplasmic β-catenin increases its translocation to the nucleus where it activates various target genes involved in tumor development and progression. Thus, to determine the activity of the Wnt/β-catenin pathway in JEG-3 and JAR cells after treatment with 5-Aza, we utilized western blotting and qRT-PCR to examine the expression of dominant components of canonical Wnt signaling, including Dvl3, β-catenin, and p-GSK-3β; the results indicated their expressions were decreased at both the protein and mRNA levels. To further explore the Wnt/β-catenin signaling activity, IF was applied to evaluate the distribution of β-catenin and showed that in contrast to the untreated cells, β-catenin was mainly located in the plasma in JEG-3 and JAR cells after treatment with 5-Aza. Consistent with this finding, Sun et al. reported that β-catenin was stabilized in the cytoplasm on Wnt16b-mediated activation of the canonical pathway [32] . Furthermore, a Wnt activator, BML-284, could partially rescue this effect. The activity of the Wnt/β-catenin pathway in SFRP2-silencing JEG-3 and JAR cells was also assessed. The results demonstrated that the expressions of Dvl3, β-catenin, and p-GSK-3β were increased at both the protein and mRNA levels, which indicates that SFRP2 knockdown activated Wnt/β-catenin signaling. Furthermore, a Wnt inhibitor, XAV 939, partially weakened this promotive effect. Moreover, XAV 939 abrogated the stimulating effect in the EMT phenotype and stemness caused by SFRP2 knockdown among SFRP2-silencing JEG-3 and JAR cells, which was verified by western blotting of EMT markers and the Transwell assay.
Conclusion
The current study demonstrated that SFRP2 was downregulated in CC and low expressed SFRP2 could promote migration, invasion, the EMT phenotype and stemness of CC cells via Wnt/β-catenin signaling, which will provide the foundation for additional molecular studies, as well as avenues for novel diagnosis and therapeutic interventions.
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